Ascentage Pharma Group Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS15
PHASE 3 / 2-37
RECRUITING14
READOUTS ≤12 MONTHS6
READOUT SLIPPED >6 MO64%
Delay Index: of 14 active trials registered more than a year ago, 9 have moved their primary completion (readout) date by more than 6 months since first registration (median +18.9 months). See all sponsors →
Open Ascentage Pharma Group Inc. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| APG-2575 NCT04494503 |
P1/2 | Recruiting | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | 123 | 2024-10-20 |
| Phase 1b: APG-115+pembrolizumab NCT03611868 |
P1/2 | Active, not recruiting | Unresectable or Metastatic Melanoma or Advanced Solid Tumors; Melanoma | 230 | 2025-12-30 (+63 mo) |
| APG-115 NCT04785196 |
P1/2 | Recruiting | Liposarcoma; Advanced Solid Tumor | 95 | 2026-04 (+24 mo) |
| APG-2575 NCT06182969 |
P1/2 | Recruiting | SLE | 40 | 2026-04 |
| APG-115 NCT04496349 |
P2 | Recruiting | T-Prolymphocytic Leukemia; Non-Hodgkins Lymphoma | 78 | 2026-05-31 (+58 mo) |
| APG2575 NCT05147467 |
P2 | Recruiting | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | 75 | 2026-12 (+38 mo) |
| lisaftoclax +BTK inhibitor NCT06104566 |
P3 | Recruiting | CLL/SLL | 400 | 2026-12-31 (+14 mo) |
| Olverembatinib NCT06640361 |
P3 | Recruiting | GIST | 40 | 2027-03-31 |
| APG-115 NCT05701306 |
P1/2 | Recruiting | Neuroblastoma; Solid Tumor | 100 | 2027-06-01 (+12 mo) |
| POLARIS-2 NCT06423911 |
P3 | Recruiting | Chronic Myeloid Leukemia; CML | 333 | 2027-06-30 (+19 mo) |
| Lisaftoclax (APG-2575) NCT06319456 |
P3 | Recruiting | CLL/SLL | 344 | 2027-08 |
| Olverembatinib NCT06051409 |
P3 | Recruiting | Ph+ ALL; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | 350 | 2027-12-31 (+36 mo) |
| APG-2575(Lisaftoclax ) NCT06389292 |
P3 | Recruiting | Acute Myeloid Leukemia | 486 | 2028-05-25 |
| Lisaftoclax (APG-2575) NCT04501120 |
P1/2 | Recruiting | Relapsed/Refractory Acute Myeloid Leukaemia; Myeloid Malignancy | 682 | 2028-09 (+73 mo) |
| Lisaftoclax (APG-2575) NCT06641414 |
P3 | Recruiting | Higher-risk Myelodysplastic Syndrome | 490 | 2029-06 |